A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Study sponsor: Verastem, Inc. · VSTM
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-12Estimated
Enrollment · participants616Estimated
Source updated2026-11-10Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.